blinatumomab,inotuzumab,venetoclax
pfizer,amgen,ucb pharmaceuticals,roche,astellas,abbvie
['leusm', 'blinatumomab', 'venetoclax', 'inotuzumab']
#ash22 #leusm jain: n=24 throughout dose escalation (started w q3wk dosing, now weekly), high blast burden (median 76%) at treatment. one dlt (myelosuppression) in highest dose cohort. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)